target product profile
accelerated healing of surface wounds
- neurotrophic keratitis (initial product)
- dry eye (second product)
- skin wounds
- mucous membranes
- indications
- signs/symptoms of moderate or severe NK
- signs/symptoms of moderate or severe dry eye
- epithelial eye damage (wounds), eye burns
attributes
- allogeneic platelet-rich plasma-derived growth factors
- hyaluronic acid (ophthalmic products) chitosan (dermal products)
- product format
- Product 1: high concentration eye drop
- product 2: low concentration eye drop
- multiuse, sterile, no preservatives
mechanism of action
ECI has developed a method to extract, purify and pathogen inactivate a multitude of growth factors from allogeneic platelet-rich plasma. We have formulated these growth factors and other key PRP-derived constituents with novel excipients to enhance their ability to adhere to mucosal membranes and wounds.
Our products harness a complex blend of synergistic growth factors such as NGF, PDGF, TGF-β, VEGF, EGF, and IGF to accelerate corneal wound healing and stimulate corneal re-innervation, addressing neurotrophic keratitis, dry eye disease and a number of other ophthalmic indications.
These factors activate critical intracellular signaling pathways that promote cellular proliferation, migration, regional re-innervation, and extracellular matrix remodeling—essential steps for re-epithelialization and tissue repair. Additional PRP-derived constituents modulate the inflammatory response to create a conducive healing environment and provide neurotrophic support that further facilitates nerve regeneration and restoration of corneal sensitivity.
Its allogeneic nature enables product availability, while our novel manufacturing process ensures high biocompatibility and safety, making it an effective therapeutic strategy for enhancing corneal recovery.
why platelet-rich plasma
resembles natural tears
growth factors
proteins
embraced by physicians
patient acceptance
extensive clinical data
why hyaluronic acid
safe medical grade available
accelerates wound healing
non-immunogenic/ biodegradable
used in multiple ophthalmic applications
increases muchoadhesiveness
why chitosan
safe medical grade available
accelerates wound healing
anti-microbial
non-immunogenic/ biodegradable
versatile excipient
learn more about:
our products
Our therapeutic formulation is suitable for a variety of products, including liquid eye drops, gels, ointments, contact lenses, contoured bandages, and wound dressings. Initially, ECI is pursuing ophthalmic indications for neurotrophic keratopathy (NK) and dry eye disease (DED).
ECI’s pipeline includes indications for ophthalmic burns, epithelial defects, endothelial diseases, limb stem cell deficiency, ocular graft-versus-host disease (GvHD), corneal abrasions, and chronic wounds.
our patients
Patients who experience conditions ranging from neurotrophic keratitis (NK) to dry eye disease (DED), wounds, or burns may benefit from our fusion of plasma and HA as a forward-thinking and potent strategy to potentially address their conditions with easier access and fewer side effects.
our platform
Our platform leverages growth factors derived from donated human platelet-rich plasma and proprietary hyaluronic acid (HA) or chitosan. The tissue-repairing benefits of plasma-derived products, combined with the sustained action and impact of HA or chitosan, may provide relief and long-lasting therapeutic action.